EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms

Gábor Holló iD

Expert Opinion on Drug Safety · 2025

DOI: 10.1080/14740338.2024.2436062 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Opinion on Drug Safety, 2025. Verfasst von Gábor Holló. Beteiligte Einrichtung: Tutkimusz Ltd, Solymár, Hungary. Hauptthemen laut MEDLINE: Hyperemia, Glaucoma, Antihypertensive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Santen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Adherence to therapy is fundamental for glaucoma management. Side effects of topical intraocular pressure (IOP)-lowering medications must be managed effectively to maintain adherence to the treatment plan and avoid disease progression. Ocular hyperemia is the most common side effect of topical IOP-lowering medications. It develops either as part of the mechanism of action of an IOP-lowering medication, usually requiring no medical intervention, or as a sign of allergy or toxicity, usually requiring intervention. Therefore, differentiating between types of ocular hyperemia is clinically important. AREAS COVERED: This clinically oriented narrative review explains the various types of topical glaucoma medication-induced ocular hyperemia, describing the underlying causes, mechanisms of development, and areas involved. Five types of ocular hyperemia associated with IOP-lowering medications are described, relating to the effects of preservatives and active ingredients in mono- and combination therapies. Relevant studies were identified through targeted searches of PubMed and Google Scholar, conducted in August 2024. EXPERT OPINION: Clinicians should identify the type and severity of ocular hyperemia related to IOP-lowering medications and, accordingly, remove allergenic or toxic agents from therapy. Patients should be advised to continue treatment if ocular hyperemia is mild, especially if it is an expected side effect of the medication. Glaucoma is often treated with eye drops containing medications that lower pressure within the eye – which is known as intraocular pressure, or IOP. These medications are essential to preserve vision and prevent worsening of glaucoma. They may have side effects, however. The most common is a reddening of the ocular surface, known as ocular hyperemia. It is usually not a dangerous condition, but it can be uncomfortable and make patients feel anxious. This may cause some patients to stop using their eye drops, leading to an increase in IOP and glaucoma progression. In some cases, ocular hyperemia is a sign of an allergic reaction to an eye drop ingredient or a reaction to preservatives used in the eye drops – this needs immediate action and a change in treatment. Without an educated understanding of the possible background mechanisms of ocular hyperemia and a detailed examination of the patient, ocular hyperemia may look very similar in most patients. This clinically oriented review explains the main types of ocular hyperemia associated with glaucoma medications, looks at the potential causes, and examines how treatments can be changed to manage ocular hyperemia and, at the same time, keep glaucoma under control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperemiaGlaucomaAntihypertensive AgentsHumansIntraocular PressureOphthalmic SolutionsPreservatives, PharmaceuticalSeverity of Illness IndexAnimalsMedication AdherenceDisease Progression

Stichwörter der Autor:innen

Conjunctival hyperemiaRho-kinase inhibitorepiscleral venous pressureglaucomaintraocular pressureocular hyperemiaside effecttopical medication

Substanzen

Antihypertensive AgentsOphthalmic SolutionsPreservatives, Pharmaceutical

Autor:innen und Institutionen

  • Tutkimusz Ltd, Solymár, Hungary.
  • Eye Center, Prima Medica Health Centers, Budapest, Hungary.

ORCID-Profile: Gábor Holló

Förderung

  • Santen

Zitieren

APA

Holló, G. (2025). Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2024.2436062

Vancouver

Holló G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opinion on Drug Safety. 2025. doi:10.1080/14740338.2024.2436062

BibTeX
@article{Holl2025,
  author = {Holló, Gábor},
  title = {Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms},
  journal = {Expert Opinion on Drug Safety},
  year = {2025},
  doi = {10.1080/14740338.2024.2436062}
}
Kostenlos starten →